Association between serious ischemic cardiac outcomes and medications used to treat diabetes.
about
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesComparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review14-Year risk of all-cause mortality according to hypoglycaemic drug exposure in a general populationRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolFibrin clot structure and platelet aggregation in patients with aspirin treatment failure.Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisRisk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulinA review of cardiovascular outcomes in the treatment of people with type 2 diabetes.Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetesRosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort studyExplaining Racial/Ethnic Dietary Patterns in Relation to Type 2 Diabetes: An Analysis of NHANES 2007-2012.Risk of disseminated intravascular coagulation in patients with type 2 diabetes mellitus: retrospective cohort study.The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.Review of approved pioglitazone combinations for type 2 diabetes.Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?Thiazolidinedione safety.Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom.Inappropriate pharmacological treatment in older adults affected by cardiovascular disease and other chronic comorbidities: a systematic literature review to identify potentially inappropriate prescription indicators.Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.Self-management levels of diet and metabolic risk factors according to disease duration in patients with type 2 diabetes.Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.Medical Record Databases
P2860
Q24632655-DD8595CF-109C-4EE4-AC2D-330F398B4CFDQ28082405-A0A7988B-9693-4A63-8D9F-C656EF16B8F2Q28538095-2AF980DF-F43D-4DA9-A080-D6CB66F3D02AQ28551188-3CC65B89-7AA7-4C2E-B017-7CC7A8F4B4CFQ31126985-A5E6D408-5E40-4269-A3A2-002790B2B573Q33880174-AF7A007D-E6BA-4335-BE24-C7F507E2358CQ34099031-940FD8E6-288C-4A29-8CC8-94D4087F351CQ34620604-71FF8027-F14E-476F-A6C8-C03AE8360868Q34726469-982F5BC4-D3F7-4238-BC5D-B5C150634069Q35936644-A3E7B108-5082-475A-ABFD-1C46B0A151B9Q36103818-7133E609-0D67-4DC6-B0CB-AC87EA86997CQ36639308-F726F2F1-66BB-455A-BDDF-1D5AE3D06E09Q36730207-AF3A2FA6-0352-4C01-94C1-7CF15161AF11Q37208292-200DA2F0-0FAC-4C7B-AE68-EB9AE8BE3B1FQ37310162-55FC0C31-425D-49FD-9485-6804BCE994D1Q37354092-A022FA89-F236-46DB-9EA6-60FFD9069F8BQ37612236-57BB7D1C-3324-4741-BC8B-35317DF85E1CQ37652799-B769820F-5B4D-4496-8E48-83DFE3DE8920Q37884618-B936E9B1-2320-4FFE-9648-8589C995F820Q37898749-D3DC34C1-FFB7-4A20-8637-9F0D288E930EQ38012205-488FFAE2-629B-4662-BA43-2FF78A70E188Q38071018-DBE8186C-A575-4CF7-B61B-CF4380C75BEFQ38219482-7EC546B5-217D-4CC5-9257-22F6349FEE01Q38248399-FE313A3F-9607-4786-B843-0F2DAAF263EDQ38641190-95412163-BA97-4878-B0AA-529EE11B5804Q38827838-763081EC-B7D7-429F-B108-2A1F45B58771Q38841043-FB1E45CD-3E28-4087-B632-8416A1109CC5Q40212883-F55F5D47-1E5C-40DD-AFBE-09F8864939E5Q43063161-FFB512B8-3E0A-407F-8B38-E9E5AD5190A5Q44264038-1440CDA9-E57D-4FE7-A74E-2F2F54F3D399Q46034115-1BB5DA09-34E6-465D-966C-31D590058D86Q49334204-0A1CBDE4-5B2A-4E58-B144-44B937877CA7Q53081527-BE5AC3F0-2961-45E1-A5F4-971532AE1D34Q57299690-B1832B5E-BE71-4C71-AFE0-5A078967307F
P2860
Association between serious ischemic cardiac outcomes and medications used to treat diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association between serious is ...... ations used to treat diabetes.
@en
Association between serious is ...... ations used to treat diabetes.
@nl
type
label
Association between serious is ...... ations used to treat diabetes.
@en
Association between serious is ...... ations used to treat diabetes.
@nl
prefLabel
Association between serious is ...... ations used to treat diabetes.
@en
Association between serious is ...... ations used to treat diabetes.
@nl
P2093
P2860
P356
P1476
Association between serious is ...... ations used to treat diabetes.
@en
P2093
Brian L Strom
David J Margolis
Ole Hoffstad
P2860
P304
P356
10.1002/PDS.1630
P577
2008-08-01T00:00:00Z